| CAS NO: | 2443767-35-7 |
| 包装 | 价格(元) |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Cas No. | 2443767-35-7 |
| 别名 | DBPR114 |
| Canonical SMILES | O=C(NC1=CC(Cl)=CC=C1)NC2=NC=C(S2)CCNC3=NC=NC4=C3C=CC(OCCCN(C)C)=C4 |
| 分子式 | C25H28ClN7O2S |
| 分子量 | 526.05 |
| 溶解度 | DMSO: 125 mg/mL (237.62 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | BPR1K871 is a potent and selective dual FLT3/AURKA inhibitor with IC50s of 19 nM and 22 nM for FLT3 and AURKA, respectively, acts as a preclinical development candidate for anti-cancer therapy[1]. IC50: 19 nM (FLT3), 22 nM (AURKA)[1] BPR1K871 shows potent anti-proliferative activities in MOLM-13 and MV4-11 AML cells with an EC50 of ~ 5 nM[1]. BPR1K871 is a multi-kinase inhibitor for the treatment of acute myeloid leukemia (AML) and solid tumors[1]. [1]. Hsu YC, et al. Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation. 2016 Dec 27; 7(52): 86239-86256. |
m.cnreagent.com